

CITATION REPORT

List of articles citing

A transcriptional repressor co-regulatory network governing androgen response in prostate cancers

DOI: 10.1038/emboj.2012.112
EMBO Journal, 2012, 31, 2810-23.

Source: <https://exaly.com/paper-pdf/52306447/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
133	ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss. 2013 , 19, 1023-9		205
132	Interplay between genomic alterations and androgen receptor signaling during prostate cancer development and progression. 2013 , 4, 61-9		37
131	Recurrent deletion of 3p13 targets multiple tumour suppressor genes and defines a distinct subgroup of aggressive ERG fusion-positive prostate cancers. 2013 , 231, 130-41		112
130	Epigenetic regulation of hepatocellular carcinoma in non-alcoholic fatty liver disease. 2013 , 23, 471-82		66
129	Transcriptional network of androgen receptor in prostate cancer progression. 2013 , 20, 756-68		42
128	Sequencing the transcriptional network of androgen receptor in prostate cancer. <i>Cancer Letters</i> , 2013 , 340, 254-60	9.9	10
127	Loss of PTEN is associated with aggressive behavior in ERG-positive prostate cancer. 2013 , 22, 2333-44		104
126	Molecular pathogenesis and progression of prostate cancer. 2013 , 40, 244-58		78
125	Multifaceted role of EZH2 in breast and prostate tumorigenesis: epigenetics and beyond. 2013 , 8, 464-76		66
124	Androgen receptor-target genes in african american prostate cancer disparities. 2013 , 2013, 763569		36
123	Translational bioinformatics for diagnostic and prognostic prediction of prostate cancer in the next-generation sequencing era. 2013 , 2013, 901578		26
122	FoxA1 specifies unique androgen and glucocorticoid receptor binding events in prostate cancer cells. 2013 , 73, 1570-80		155
121	NIPP1 maintains EZH2 phosphorylation and promoter occupancy at proliferation-related target genes. 2013 , 41, 842-54		31
120	Class I lysine deacetylases facilitate glucocorticoid-induced transcription. 2013 , 288, 28900-12		17
119	The ETS domain transcription factor ELK1 directs a critical component of growth signaling by the androgen receptor in prostate cancer cells. 2013 , 288, 11047-65		47
118	SAMSN1 is highly expressed and associated with a poor survival in glioblastoma multiforme. 2013 , 8, e81905		22
117	Androgen receptor activation in castration-recurrent prostate cancer: the role of Src-family and Ack1 tyrosine kinases. 2014 , 10, 620-6		22

116	Influence of oncogenic transcription factors on chromatin conformation and implications in prostate cancer. 2014 , 7, 81-91		3
115	The primary microRNA-208b interacts with Polycomb-group protein, Ezh2, to regulate gene expression in the heart. 2014 , 42, 790-803		47
114	Androgen receptor co-regulatory networks in castration-resistant prostate cancer. 2014 , 21, R1-R11		15
113	The Polycomb group (PcG) protein EZH2 supports the survival of PAX3-FOXO1 alveolar rhabdomyosarcoma by repressing FBXO32 (Atrogin1/MAFbx). <i>Oncogene</i> , 2014 , 33, 4173-84	9.2	49
112	Scaffold attachment factor B1 regulates the androgen receptor in concert with the growth inhibitory kinase MST1 and the methyltransferase EZH2. <i>Oncogene</i> , 2014 , 33, 3235-45	9.2	21
111	Integrative analysis of FOXP1 function reveals a tumor-suppressive effect in prostate cancer. 2014 , 28, 2012-24		42
110	SUMOylation modulates the transcriptional activity of androgen receptor in a target gene and pathway selective manner. 2014 , 42, 8310-9		47
109	Minireview: The versatile roles of lysine deacetylases in steroid receptor signaling. 2014 , 28, 607-21		5
108	Role of ChIP-seq in the discovery of transcription factor binding sites, differential gene regulation mechanism, epigenetic marks and beyond. 2014 , 13, 2847-52		78
107	CtBP2 modulates the androgen receptor to promote prostate cancer progression. 2014 , 74, 6542-53		41
106	HEXIM1 plays a critical role in the inhibition of the androgen receptor by anti-androgens. 2014 , 462, 315-27		15
105	Tissue-specific pioneer factors associate with androgen receptor cistromes and transcription programs. <i>EMBO Journal</i> , 2014 , 33, 312-26	13	82
104	Minireview: Conversing with chromatin: the language of nuclear receptors. 2014 , 28, 3-15		12
103	Epigenetic modifications in prostate cancer. 2014 , 6, 415-26		38
102	Ablation of the oncogenic transcription factor ERG by deubiquitinase inhibition in prostate cancer. 2014 , 111, 4251-6		94
101	Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis. <i>Oncogene</i> , 2014 , 33, 2815-25	9.2	236
100	SOCS2 mediates the cross talk between androgen and growth hormone signaling in prostate cancer. 2014 , 35, 24-33		34
99	Pharmacological inhibition of EZH2 as a promising differentiation therapy in embryonal RMS. 2014 , 14, 139		48

98	Identification of novel TMPRSS2:ERG mechanisms in prostate cancer metastasis: involvement of MMP9 and PLXNA2. <i>Oncogene</i> , 2014 , 33, 2204-14	9.2	51
97	The predictive value of ERG protein expression for development of castration-resistant prostate cancer in hormone-naïve advanced prostate cancer treated with primary androgen deprivation therapy. 2015 , 75, 1499-509		11
96	Systematic enrichment analysis of potentially functional regions for 103 prostate cancer risk-associated loci. 2015 , 75, 1264-76		30
95	RUNX1, an androgen- and EZH2-regulated gene, has differential roles in AR-dependent and -independent prostate cancer. <i>Oncotarget</i> , 2015 , 6, 2263-76	3.3	54
94	Epigenetic-mediated reprogramming of pancreatic endocrine cells. 2015 , 22, 1483-95		2
93	Active heat shock transcription factor 1 supports migration of the melanoma cells via vinculin down-regulation. 2015 , 27, 394-401		26
92	Determinants of Receptor- and Tissue-Specific Actions in Androgen Signaling. 2015 , 36, 357-84		79
91	A novel prostate cancer therapeutic strategy using icaritin-activated arylhydrocarbon-receptor to co-target androgen receptor and its splice variants. 2015 , 36, 757-68		39
90	Identification of a Novel Coregulator, SH3YL1, That Interacts With the Androgen Receptor N-Terminus. 2015 , 29, 1426-39		14
89	The Deubiquitinating Enzyme USP7 Regulates Androgen Receptor Activity by Modulating Its Binding to Chromatin. 2015 , 290, 21713-23		39
88	MDC1 functionally identified as an androgen receptor co-activator participates in suppression of prostate cancer. 2015 , 43, 4893-908		31
87	One-Carbon Metabolism in Prostate Cancer: The Role of Androgen Signaling. 2016 , 17,		27
86	The Germ Cell Gene TDRD1 as an ERG Target Gene and a Novel Prostate Cancer Biomarker. 2016 , 76, 1271-84		12
85	Yin Yang 1-mediated epigenetic silencing of tumour-suppressive microRNAs activates nuclear factor- κ B in hepatocellular carcinoma. 2016 , 238, 651-64		35
84	An Interaction with Ewing's Sarcoma Breakpoint Protein EWS Defines a Specific Oncogenic Mechanism of ETS Factors Rearranged in Prostate Cancer. <i>Cell Reports</i> , 2016 , 17, 1289-1301	10.6	27
83	Identification of an AR Mutation-Negative Class of Androgen Insensitivity by Determining Endogenous AR Activity. 2016 , 101, 4468-4477		49
82	Regulated expression of the prostacyclin receptor (IP) gene by androgens within the vasculature: Combined role for androgens and serum cholesterol. 2016 , 1859, 1333-51		6
81	Global analysis of transcription in castration-resistant prostate cancer cells uncovers active enhancers and direct androgen receptor targets. 2016 , 6, 33510		21

80	Mutations and deletions of PRC2 in prostate cancer. 2016 , 38, 446-54		15
79	The oncogene ERG: a key factor in prostate cancer. <i>Oncogene</i> , 2016 , 35, 403-14	9.2	127
78	Stem cells and the role of ETS transcription factors in the differentiation hierarchy of normal and malignant prostate epithelium. 2017 , 166, 68-83		8
77	A review of estrogen receptor/androgen receptor genomics in male breast cancer. 2017 , 24, R27-R34		18
76	Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer. 2017 , 31, 532-548.e7		57
75	Transcriptional regulation of core autophagy and lysosomal genes by the androgen receptor promotes prostate cancer progression. 2017 , 13, 506-521		63
74	Phosphorylation of the oncogenic transcription factor ERG in prostate cells dissociates polycomb repressive complex 2, allowing target gene activation. 2017 , 292, 17225-17235		10
73	DNA and Histone Methylation in Prostate Cancer. 2017 , 489-529		
72	DNA Sequence Constraints Define Functionally Active Steroid Nuclear Receptor Binding Sites in Chromatin. 2017 , 158, 3212-3234		14
71	A new transgenic mouse model for conditional overexpression of the Polycomb Group protein EZH2. 2017 , 26, 187-196		6
70	The expression of AURKA is androgen regulated in castration-resistant prostate cancer. 2017 , 7, 17978		23
69	The Genomic Impact of DNA CpG Methylation on Gene Expression; Relationships in Prostate Cancer. 2017 , 7,		61
68	An Efficient Network Motif Discovery Approach for Co-Regulatory Networks. 2018 , 6, 14151-14158		15
67	GLUT12 promotes prostate cancer cell growth and is regulated by androgens and CaMKK2 signaling. 2018 , 25, 453-469		28
66	Nuclear receptors in cancer - uncovering new and evolving roles through genomic analysis. 2018 , 19, 160-174		46
65	Transcriptional Regulation in Prostate Cancer. 2018 , 8,		34
64	Genome-wide analysis of AR binding and comparison with transcript expression in primary human fetal prostate fibroblasts and cancer associated fibroblasts. 2018 , 471, 1-14		25
63	Validation of histone deacetylase 3 as a therapeutic target in castration-resistant prostate cancer. 2018 , 78, 266-277		17

62	TPRSS2:ERG gene fusion expression regulates bone markers and enhances the osteoblastic phenotype of prostate cancer bone metastases. <i>Cancer Letters</i> , 2018 , 438, 32-43	9.9	12
61	Identification of Androgen Receptor Modulators in a Prostate Cancer Cell Line Microarray Compendium. 2018 , 166, 146-162		14
60	KM-express: an integrated online patient survival and gene expression analysis tool for the identification and functional characterization of prognostic markers in breast and prostate cancers. 2018 , 2018,		15
59	Novel lncRNA Regulates Prostate Cancer Cell Migration and Invasion through AR Signaling. 2018 , 16, 1865-1878		59
58	KDM8/JMJD5 as a dual coactivator of AR and PKM2 integrates AR/EZH2 network and tumor metabolism in CRPC. <i>Oncogene</i> , 2019 , 38, 17-32	9.2	42
57	Decoding the Inversion Symmetry Underlying Transcription Factor DNA-Binding Specificity and Functionality in the Genome. 2019 , 15, 552-591		1
56	The Transcription Factor ERG Regulates Super-Enhancers Associated With an Endothelial-Specific Gene Expression Program. 2019 , 124, 1337-1349		34
55	Epigenetics of Prostate Cancer and Novel Chemopreventive and Therapeutic Approaches. 2019 , 287-308		1
54	An AR-ERG transcriptional signature defined by long-range chromatin interactomes in prostate cancer cells. 2019 , 29, 223-235		24
53	Proteomics Analysis of Formalin Fixed Paraffin Embedded Tissues in the Investigation of Prostate Cancer. 2020 , 19, 2631-2642		11
52	BCOR-coupled H2A monoubiquitination represses a subset of androgen receptor target genes regulating prostate cancer proliferation. <i>Oncogene</i> , 2020 , 39, 2391-2407	9.2	6
51	The Inhibition of the Histone Methyltransferase EZH2 by DZNEP or siRNA Demonstrates Its Involvement in , , and Gene Regulation in Prostate Cancer. 2020 , 24, 116-118		4
50	Core regulatory circuitries in defining cancer cell identity across the malignant spectrum. 2020 , 10, 200121		1
49	CBF β SMHC Affects Genome-wide Polycomb Repressive Complex 1 Activity in Acute Myeloid Leukemia. <i>Cell Reports</i> , 2020 , 30, 299-307.e3	10.6	5
48	Loss of a Negative Feedback Loop between IRF8 and AR Promotes Prostate Cancer Growth and Enzalutamide Resistance. 2020 , 80, 2927-2939		7
47	Integrative analysis of AR-mediated transcriptional regulatory network reveals IRF1 as an inhibitor of prostate cancer progression. 2020 , 80, 640-652		1
46	Dual functions of SPOP and ERG dictate androgen therapy responses in prostate cancer. 2021 , 12, 734		10
45	MSH2-deficient prostate tumours have a distinct immune response and clinical outcome compared to MSH2-deficient colorectal or endometrial cancer. 2021 , 24, 1167-1180		0

44	EZH2-induced lysine K362 methylation enhances TMPRSS2-ERG oncogenic activity in prostate cancer. 2021 , 12, 4147		2
43	Ras/ERK and PI3K/AKT signaling differentially regulate oncogenic ERG mediated transcription in prostate cells. 2021 , 17, e1009708		1
42	Chromatin and Epigenetic Dysregulation of Prostate Cancer Development, Progression, and Therapeutic Response. <i>Cancers</i> , 2021 , 13,	6.6	3
41	Identification of Androgen Receptor Metabolic Correlome Reveals the Repression of Ceramide Kinase by Androgens. <i>Cancers</i> , 2021 , 13,	6.6	2
40	Transcriptional network involving ERG and AR orchestrates Distal-less/homeobox-1 mediated prostate cancer progression. 2021 , 12, 5325		2
39	Androgen-Dependent Oncogenic Activation of ETS Transcription Factors by Recurrent Gene Fusions in Prostate Cancer: Biological and Clinical Implications. 2013 , 307-328		6
38	Oncogenic ETS Factors in Prostate Cancer. 2019 , 1210, 409-436		17
37	Dual Functions of SPOP and ERG Dictate Androgen Therapy Responses in Prostate Cancer.		1
36	Recent advances in prostate cancer research: large-scale genomic analyses reveal novel driver mutations and DNA repair defects. 2018 , 7,		22
35	Androgen receptor enhancer usage and the chromatin regulatory landscape in human prostate cancers. 2019 , 26, R267-R285		8
34	The ubiquitin ligase TRIM25 targets ERG for degradation in prostate cancer. <i>Oncotarget</i> , 2016 , 7, 64921-64931	6.6	25
33	Integrated bioinformatics analysis of chromatin regulator EZH2 in regulating mRNA and lncRNA expression by ChIP sequencing and RNA sequencing. <i>Oncotarget</i> , 2016 , 7, 81715-81726	3.3	7
32	The combined effect of USP7 inhibitors and PARP inhibitors in hormone-sensitive and castration-resistant prostate cancer cells. <i>Oncotarget</i> , 2017 , 8, 31815-31829	3.3	45
31	Discovery and characterization of small molecules targeting the DNA-binding ETS domain of ERG in prostate cancer. <i>Oncotarget</i> , 2017 , 8, 42438-42454	3.3	28
30	Molecular pathways and targets in prostate cancer. <i>Oncotarget</i> , 2014 , 5, 7217-59	3.3	68
29	The tumor suppressive miR-200b subfamily is an ERG target gene in human prostate tumors. <i>Oncotarget</i> , 2016 , 7, 37993-38003	3.3	17
28	Androgen receptor genomic regulation. <i>Translational Andrology and Urology</i> , 2013 , 2, 157-177	2.3	38
27	Androgen receptor epigenetics. <i>Translational Andrology and Urology</i> , 2013 , 2, 148-157	2.3	14

26	Androgen receptor functions in prostate cancer development and progression. <i>Asian Journal of Andrology</i> , 2014 , 16, 561-4	2.8	8
25	Transcriptional repression by androgen receptor: roles in castration-resistant prostate cancer. <i>Asian Journal of Andrology</i> , 2019 , 21, 215-223	2.8	13
24	HOXB13 suppresses de novo lipogenesis through HDAC3-mediated epigenetic reprogramming.		
23	Single-cell analysis reveals androgen receptor regulates the ER-to-Golgi trafficking pathway with CREB3L2 to drive prostate cancer progression. <i>Oncogene</i> , 2021 , 40, 6479-6493	9.2	0
22	Roles of Androgen Receptor Coregulators and Cell Signaling in the Regulation of Androgen-Responsive Genes. 2013 , 1-11		
21	Selective and Classical Androgen Response Elements in Androgen-Regulated Gene Expression. 2013 , 13-27		
20	MSH2 is Inactivated by Multiple Mechanisms in Prostate Tumors, Leading to a Distinct Immune Response and Clinical Outcome Compared to MSH2 Deficient Colorectal Cancer. <i>SSRN Electronic Journal</i> ,	1	
19	A novel long noncoding RNA LINC00844 regulates prostate cancer cell migration and invasion through androgen receptor signaling.		
18	Transcriptional network involving ERG and AR orchestrates Distal-Less Homeobox 1 mediated prostate cancer progression.		
17	Dynamic expression of SNAI2 in prostate cancer predicts tumor progression and drug sensitivity. <i>Molecular Oncology</i> , 2021 ,	7.9	1
16	ETS factors in prostate cancer.. <i>Cancer Letters</i> , 2022 ,	9.9	3
15	Past, Current, and Future Strategies to Target ERG Fusion-Positive Prostate Cancer.. <i>Cancers</i> , 2022 , 14,	6.6	0
14	The mTOR chromatin-bound interactome in prostate cancer.. <i>Cell Reports</i> , 2022 , 38, 110534	10.6	1
13	Roles of Key Epigenetic Regulators in the Gene Transcription and Progression of Prostate Cancer.. <i>Frontiers in Molecular Biosciences</i> , 2021 , 8, 743376	5.6	
12	Human ERG Oncoprotein Represses Chip/LDB1 LIM-Domain Binding Gene in Drosophila.		
11	Evidence that HDAC7 acts as an epigenetic leader of AR acetylation through NCoR-HDAC3 dissociation. <i>Cell Chemical Biology</i> , 2022 ,	8.2	0
10	A cryptic transactivation domain of EZH2 binds AR and AR splice variant promoting oncogene activation and tumorous transformation.		
9	Reformation of the chondroitin sulfate glyocalyx enables progression of AR-independent prostate cancer. 2022 , 13,		1

- 8 Epigenetic Coregulation of Androgen Receptor Signaling. **2022**, 277-293 ○
- 7 Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB synergizes enzalutamide treatment in advanced prostate cancer. ○
- 6 To bind or not to bind: Cistromic reprogramming in prostate cancer. 12, 1
- 5 A cryptic transactivation domain of EZH2 binds AR and AR β splice variant, promoting oncogene activation and tumorous transformation. ○
- 4 Extensive germline-somatic interplay contributes to prostate cancer progression through HNF1B co-option of TMPRSS2-ERG. **2022**, 13, ○
- 3 Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB synergizes enzalutamide treatment in advanced prostate cancer. 1
- 2 Beyond expression: role of phosphorylated residues of EZH2 in lineage plasticity in prostate cancer. ○
- 1 Transcription networks rewire gene repertoire to coordinate cellular reprogramming in prostate cancer. **2023**, 89, 76-91 ○